Video

Dr. Rogers on Data for Ibrutinib in Hairy Cell Leukemia

Kerry Rogers, MD, discusses the results from an ongoing phase II trial investigating ibrutinib in patients with relapsed/refractory hairy cell leukemia. Because this represents a very rare patient population, accrual began in 2013, and these data reflect on a small portion of the 39 patients enrolled.

Kerry Rogers, MD, assistant professor at the Ohio State University Comprehensive Cancer Center, discusses the results from an ongoing phase II trial investigating ibrutinib (Imbruvica) in patients with relapsed/refractory hairy cell leukemia in an interview during the 2019 Hairy Cell Leukemia Foundation Annual Conference. Because this represents a very rare patient population, accrual for the trial began in 2013, and these data reflect a small portion of the 39 patients enrolled.

The overall response rate in these patients was just over 50%, says Rogers. This may not be an outstanding response, but it is promising for such a rare patient population with limited treatment options, she explains. The estimated 3-year progression-free survival (PFS) rate was just under 75%, which is very encouraging, Rogers adds. The PFS is the major benefit from ibrutinib in this patient population.

<<< View more from the 2019 Hairy Cell Leukemia Foundation Annual Conference

Related Videos
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie